[{"orgOrder":0,"company":"AI VIVO","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Imatinib Mesylate","moa":"PTK","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AI VIVO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AI VIVO \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AI VIVO \/ Undisclosed"},{"orgOrder":0,"company":"Exvastat","sponsor":"Innovative Medicines Initiative","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Imatinib Mesylate","moa":"PTK","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exvastat","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Exvastat \/ Innovative Medicines Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Exvastat \/ Innovative Medicines Initiative"},{"orgOrder":0,"company":"YD Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"YD Life Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"YD Life Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"YD Life Science \/ Not Applicable"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Aerami","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Imatinib Mesylate","moa":"PTK","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Vectura Ltd \/ Aerami","highestDevelopmentStatusID":"5","companyTruncated":"Vectura Ltd \/ Aerami"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"RA Capital Incubator","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"Imatinib Mesylate","moa":"PDGF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.070000000000000007,"dosageForm":"Inhalation","sponsorNew":"Aerovate Therapeutics \/ RA Capital Incubator","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ RA Capital Incubator"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Hangzhou Chance Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Imatinib Mesylate","moa":"PDGFRB","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aerami Therapeutics \/ Hangzhou Chance Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Hangzhou Chance Pharmaceuticals"},{"orgOrder":0,"company":"PH Precision Med","sponsor":"Tenax Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Imatinib Mesylate","moa":"PDGFRB","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"PH Precision Med","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"oral","sponsorNew":"PH Precision Med \/ Tenax Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"PH Precision Med \/ Tenax Therapeutics"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"FoxWayne Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Merger","leadProduct":"Imatinib Mesylate","moa":"ABL1 gene","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aerami Therapeutics \/ FoxWayne Enterprises","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ FoxWayne Enterprises"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"PDGF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Dry Powder Inhalation","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"ABL1 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder For Inhalation","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"PDGFRB","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"PDGF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Dry Powder Inhalation","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"PDGF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"PDGF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Imatinib Mesylate","moa":"PDGF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Enteric Capsule","sponsorNew":"Tenax Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Dry Powder Inhalation","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"Enteric Capsule","sponsorNew":"Tenax Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Asciminib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Shorla Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Shorla Oncology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Shorla Oncology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shorla Oncology \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Imatinib (mesylate)
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
